Last reviewed · How we verify
TYPHIBEV
At a glance
| Generic name | TYPHIBEV |
|---|---|
| Also known as | Biological E. Limiteds Typhoid Vi-CRM197 conjugate vaccine, Typhoid Vi-CRM197 conjugate vaccine, Biological E. Limited's Typhoid Vi-CRM197 conjugate vaccine |
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Vellore Typhoid Vaccine Impact Trial (PHASE4)
- A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants (PHASE2)
- A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants (PHASE2)
- Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TYPHIBEV CI brief — competitive landscape report
- TYPHIBEV updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI